ATE461209T1 - Hcv ns-3 serine protease inhibitoren - Google Patents

Hcv ns-3 serine protease inhibitoren

Info

Publication number
ATE461209T1
ATE461209T1 AT05704764T AT05704764T ATE461209T1 AT E461209 T1 ATE461209 T1 AT E461209T1 AT 05704764 T AT05704764 T AT 05704764T AT 05704764 T AT05704764 T AT 05704764T AT E461209 T1 ATE461209 T1 AT E461209T1
Authority
AT
Austria
Prior art keywords
hcv
protease inhibitors
serine protease
serine
inhibitors
Prior art date
Application number
AT05704764T
Other languages
English (en)
Inventor
Asa Rosenquist
Fredrik Thorstensson
Per-Ola Johansson
Ingemar Kvarnstroem
Susana Ayesa
Bjoern Classon
Lazlo Rakos
Bertil Samuelsson
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34831013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0400199A external-priority patent/SE0400199D0/xx
Priority claimed from SE0401288A external-priority patent/SE0401288D0/xx
Priority claimed from SE0402562A external-priority patent/SE0402562D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Application granted granted Critical
Publication of ATE461209T1 publication Critical patent/ATE461209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT05704764T 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren ATE461209T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0400199A SE0400199D0 (sv) 2004-01-30 2004-01-30 HCV Protease inhbitors
SE0401288A SE0401288D0 (sv) 2004-05-19 2004-05-19 HCV NS-3 Serine Protease Inhbitors
SE0402562A SE0402562D0 (sv) 2004-10-22 2004-10-22 HCV Protease Inhbitors
PCT/SE2005/000096 WO2005073216A2 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors

Publications (1)

Publication Number Publication Date
ATE461209T1 true ATE461209T1 (de) 2010-04-15

Family

ID=34831013

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05704765T ATE448243T1 (de) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren
AT05704764T ATE461209T1 (de) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05704765T ATE448243T1 (de) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren

Country Status (32)

Country Link
US (5) US7608590B2 (de)
EP (2) EP1713822B1 (de)
JP (4) JP5248783B2 (de)
KR (3) KR20120090077A (de)
AR (2) AR047793A1 (de)
AT (2) ATE448243T1 (de)
AU (2) AU2005207816C1 (de)
BR (2) BRPI0506945A (de)
CA (2) CA2552319C (de)
CR (2) CR8540A (de)
CY (1) CY1109779T1 (de)
DE (2) DE602005019979D1 (de)
DK (2) DK1713823T3 (de)
EA (2) EA012410B1 (de)
EC (2) ECSP066725A (de)
ES (2) ES2336009T3 (de)
HR (1) HRP20100048T1 (de)
IL (2) IL176848A (de)
LU (1) LU92595I2 (de)
MY (2) MY146349A (de)
NI (1) NI200600168A (de)
NL (1) NL300703I2 (de)
NO (1) NO341392B1 (de)
NZ (2) NZ548739A (de)
PL (2) PL1713822T3 (de)
PT (1) PT1713823E (de)
RS (1) RS51243B (de)
SI (1) SI1713823T1 (de)
TW (2) TWI367211B (de)
UA (2) UA84189C2 (de)
WO (2) WO2005073195A2 (de)
ZA (1) ZA200607214B (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1713822B1 (de) * 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitoren
GEP20104926B (en) * 2004-03-30 2010-03-25 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101263156A (zh) 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
CN101273030B (zh) 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
AR055361A1 (es) * 2005-07-29 2007-08-22 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
MY141245A (en) * 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
JP2009502845A (ja) 2005-07-29 2009-01-29 メディヴィル・アクチボラグ Ｃ型肝炎ウイルスの大環状インヒビター
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0614696A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos de vìrus da hepatite c
DE602006019883D1 (de) * 2005-07-29 2011-03-10 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
ES2360417T3 (es) * 2005-07-29 2011-06-03 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
JP5426164B2 (ja) 2005-07-29 2014-02-26 ヤンセン・アールアンドデイ・アイルランド Ｃ型肝炎ウイルスの大環式インヒビター
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7655394B2 (en) * 2005-10-28 2010-02-02 Boehringer Ingelheim International Gmbh Hepatitis C virus NS2/3 activity assay
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
EP1881001A1 (de) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV-NS-3-Serinproteaseinhibitoren
EP1881002A1 (de) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV-NS-3-Serinproteaseinhibitoren
EP2518494A3 (de) * 2006-08-09 2013-11-20 Sumitomo Bakelite Company, Ltd. Zuckerketten erfassende Substanz und Verwendung davon
NZ575889A (en) 2006-10-10 2011-09-30 Medivir Ab Hcv nucleoside inhibitor
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2470568T3 (es) 2006-11-17 2014-06-24 Janssen R&D Ireland Inhibidores macroc�clicos del virus de la hepatitis C
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
ES2547386T3 (es) * 2007-01-26 2015-10-05 Kaneq Pharma Inc. Inhibidores de la PTP-1B aromáticos condensados
ES2524784T3 (es) * 2007-02-01 2014-12-12 Janssen R&D Ireland Formas polimórficas de un inhibidor macrocíclico del VHC
KR101598135B1 (ko) * 2007-02-01 2016-02-26 얀센 사이언시즈 아일랜드 유씨 Ｈｃｖ의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체
KR20090110314A (ko) * 2007-02-08 2009-10-21 티보텍 파마슈티칼즈 리미티드 피리미딘 치환된 마크로사이클릭 ｈｃｖ 억제제
ES2432590T3 (es) * 2007-02-08 2013-12-04 Janssen R&D Ireland Fenilcarbamatos macrocíclicos inhibidores del VHC
JP2010519339A (ja) 2007-02-26 2010-06-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ複製阻害剤として有用な三級アミン置換ペプチド
US20100104534A1 (en) * 2007-03-23 2010-04-29 Srikanth Venkatraman Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2009042668A2 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8304385B2 (en) 2007-11-14 2012-11-06 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
WO2009085978A1 (en) * 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CN101977915B (zh) 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012510523A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
HK1203929A1 (en) 2008-12-03 2015-11-06 普雷西迪奥制药公司 Inhibitors of hcv ns5a
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2382198T3 (pl) * 2008-12-23 2013-11-29 Janssen Pharmaceuticals Inc Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN102356080B (zh) 2009-02-27 2015-04-29 奥索-麦克尼尔-詹森药品公司 Hcv大环抑制剂的无定形盐
CA2755658A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2547645B1 (de) 2010-03-16 2018-07-04 Janssen Pharmaceuticals, Inc. Procédés et intermédiaires pour préparer un inhibiteur de protéase macrocyclique du virus de l'hépatite c
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
AU2011239974B2 (en) 2010-04-13 2015-12-03 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of HCV, a non-nucleoside and a nucleoside
EP2575866A4 (de) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc Hcv-ns5a-shemmer
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
EP2635570B1 (de) 2010-11-01 2017-12-13 RFS Pharma, LLC. Neue spezifische hcv-ns3-proteaseinhibitoren
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
TW201309690A (zh) * 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2014102102A (ru) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
WO2013041655A1 (en) 2011-09-22 2013-03-28 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
US9180193B2 (en) 2011-10-10 2015-11-10 Hoffmann-La Roche Inc. Antiviral compounds
MX2014006745A (es) 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
LT2794628T (lt) 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
PE20141423A1 (es) 2011-12-20 2014-10-16 Hoffmann La Roche Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
CA2858814A1 (en) 2012-01-12 2013-07-18 Rfs Pharma, Llc Hcv ns3 protease inhibitors
BR112014015582A8 (pt) 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105073726B (zh) 2013-01-23 2017-05-31 弗·哈夫曼-拉罗切有限公司 抗病毒三唑衍生物
CA2900319A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014152928A2 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
CA2912682C (en) 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (de) 2014-01-28 2015-07-29 Amikana.Biologics Neues Verfahren zum Testen von HCV-Proteasehemmung
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
US11480714B2 (en) 2017-10-04 2022-10-25 University Of Florida Research Foundation, Inc. Methods and compositions for improved comfort contact lens
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
EP0873519A4 (de) * 1995-12-07 2005-04-27 Scripps Research Inst Hiv-protease-inhibitoren
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
JPH11292840A (ja) * 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
WO1999067396A1 (en) 1998-06-24 1999-12-29 International Reagents Corporation Hcv-derived rna polymerase gene
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
GB9925955D0 (en) * 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
US6774212B2 (en) * 1999-12-03 2004-08-10 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
EP1268519B1 (de) 2000-04-03 2005-06-15 Vertex Pharmaceuticals Incorporated Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
DE60137207D1 (de) * 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
RU2355700C9 (ru) * 2000-07-21 2010-03-20 Шеринг Корпорейшн Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2002248147B2 (en) 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
HUP0303436A2 (hu) * 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR100926244B1 (ko) * 2001-07-11 2009-11-12 버텍스 파마슈티칼스 인코포레이티드 브릿지된 바이사이클릭 세린 프로테아제 억제제
EP1441720B8 (de) 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
KR20040077767A (ko) 2002-01-23 2004-09-06 쉐링 코포레이션 Ｃ형 간염 바이러스 감염 치료용 ｎｓ3-세린 프로테아제억제제로서의 프롤린 화합물
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MXPA04009938A (es) 2002-04-11 2004-12-13 Vertex Pharma Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP4312711B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
ES2361011T3 (es) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
WO2004002940A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Inhibitors of hcv ns5b polymerase
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
EP1408031A1 (de) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidinderivate zur Behandlung von Hepatitis C Virusinfektion
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ATE385253T1 (de) 2002-10-29 2008-02-15 Boehringer Ingelheim Int Nhibitor-resistente hcv ns3 protease
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
WO2004101602A2 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CN100363055C (zh) 2003-04-02 2008-01-23 贝林格尔·英格海姆国际有限公司 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
EP1613620A1 (de) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitoren von serinproteasen, insbesondere hcv-ns3-ns4a-protease
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
DE602004023924D1 (en) 2003-04-18 2009-12-17 Enanta Pharm Inc Ease-hemmer
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005037826A1 (en) * 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
EP1713822B1 (de) 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitoren
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
BRPI0614696A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos de vìrus da hepatite c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
DE602006019883D1 (de) 2005-07-29 2011-03-10 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
CN101273030B (zh) 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
AR055361A1 (es) 2005-07-29 2007-08-22 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
JP2009502845A (ja) 2005-07-29 2009-01-29 メディヴィル・アクチボラグ Ｃ型肝炎ウイルスの大環状インヒビター
JP5426164B2 (ja) 2005-07-29 2014-02-26 ヤンセン・アールアンドデイ・アイルランド Ｃ型肝炎ウイルスの大環式インヒビター
MY141245A (en) 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
AU2005207816A1 (en) 2005-08-11
DK1713822T3 (da) 2010-07-19
RS51243B (sr) 2010-12-31
BRPI0506948A (pt) 2007-06-12
WO2005073216A3 (en) 2005-10-06
DE602005019979D1 (en) 2010-04-29
NO341392B1 (no) 2017-10-30
JP5795619B2 (ja) 2015-10-14
HRP20100048T1 (hr) 2010-04-30
US20070161574A1 (en) 2007-07-12
KR101159575B1 (ko) 2012-07-06
SI1713823T1 (sl) 2010-04-30
EA200601399A1 (ru) 2006-12-29
US20100003216A1 (en) 2010-01-07
DE602005017582D1 (en) 2009-12-24
US7608590B2 (en) 2009-10-27
ES2336009T8 (es) 2014-11-05
EP1713822A2 (de) 2006-10-25
EA014584B1 (ru) 2010-12-30
AR048401A1 (es) 2006-04-26
MY146349A (en) 2012-08-15
CY1109779T1 (el) 2014-09-10
IL176848A0 (en) 2006-10-31
PL1713823T3 (pl) 2010-04-30
WO2005073216A2 (en) 2005-08-11
HK1104044A1 (en) 2008-01-04
KR20060126567A (ko) 2006-12-07
AU2005207815B2 (en) 2011-08-04
ES2342944T3 (es) 2010-07-19
CR8540A (es) 2009-01-16
CA2552317C (en) 2013-12-10
TW200538450A (en) 2005-12-01
KR101217036B1 (ko) 2013-01-02
CA2552319C (en) 2012-08-21
AU2005207816C1 (en) 2015-05-07
US7671032B2 (en) 2010-03-02
KR20120090077A (ko) 2012-08-16
UA84050C2 (en) 2008-09-10
IL176921A (en) 2012-03-29
KR20070009571A (ko) 2007-01-18
JP4902361B2 (ja) 2012-03-21
TW200538449A (en) 2005-12-01
NL300703I2 (nl) 2017-07-20
PL1713822T3 (pl) 2010-08-31
JP2014055161A (ja) 2014-03-27
EA200601400A1 (ru) 2007-02-27
CA2552319A1 (en) 2005-08-11
ES2336009T3 (es) 2010-04-07
NZ548740A (en) 2010-06-25
WO2005073195A2 (en) 2005-08-11
BRPI0506945A (pt) 2007-06-12
US20100166706A1 (en) 2010-07-01
ECSP066726A (es) 2006-12-29
TWI361195B (en) 2012-04-01
EP1713823B1 (de) 2009-11-11
BRPI0506948B1 (pt) 2018-09-18
NZ548739A (en) 2010-10-29
NI200600168A (es) 2016-02-11
EA012410B1 (ru) 2009-10-30
ZA200607214B (en) 2008-04-30
CR8539A (es) 2009-02-23
ATE448243T1 (de) 2009-11-15
LU92595I2 (fr) 2015-11-02
IL176921A0 (en) 2006-12-10
AR047793A1 (es) 2006-02-22
DK1713823T3 (da) 2010-03-08
WO2005073195A3 (en) 2005-09-29
US20070203072A1 (en) 2007-08-30
IL176848A (en) 2015-07-30
US20170196849A1 (en) 2017-07-13
MY153011A (en) 2014-12-31
JP5248783B2 (ja) 2013-07-31
TWI367211B (en) 2012-07-01
HK1100881A1 (en) 2007-09-28
EP1713823A2 (de) 2006-10-25
JP2007519716A (ja) 2007-07-19
US10172846B2 (en) 2019-01-08
EP1713822B1 (de) 2010-03-17
UA84189C2 (en) 2008-09-25
AU2005207816B2 (en) 2011-04-14
JP2007524670A (ja) 2007-08-30
PT1713823E (pt) 2010-02-02
JP2011140488A (ja) 2011-07-21
AU2005207815A1 (en) 2005-08-11
NO20063851L (no) 2006-08-29
ECSP066725A (es) 2006-12-29
CA2552317A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
DK1713823T3 (da) HCV NS-3 serinproteaseinhibitorer
DK1924593T3 (da) HCV NS3-proteaseinhibitorer
ATE530554T1 (de) Serinprotease-hemmer
EP2076278A4 (de) Hcv-ns3 -proteasehemmer
EP2079480A4 (de) Hcv-ns3 -proteasehemmer
IL177503A0 (en) Inhibitors of hepatitis c virus ns3 protease
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005021760D1 (de) Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
IL198401A0 (en) Hcv ns3 protease inhibitors
DE602005019971D1 (de) Inhibitoren von cysteinprotease
ATE482214T1 (de) Aspartylproteasehemmer
IL177545A0 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
EP2083844A4 (de) Inhibitoren der hcv-ns3-protease
EP2125870A4 (de) Inhibitoren von hepatitis-c-ns3-protease
EP1499336A4 (de) Proteasehemmer
DK1817276T3 (da) Cathepsin cysteine protease inhibitors
ZA200800072B (en) HCV NS3 Protease inhibitors
ATE429417T1 (de) Hiv-protease-inhibitoren
ZA200902475B (en) HCV NS3 Protease Inhibitors
EP1715920A4 (de) Cathepsincysteinproteasehemmer
SE0401288D0 (sv) HCV NS-3 Serine Protease Inhbitors
DE602004014762D1 (de) Proteasehemmer
SE0401558D0 (sv) HCV Protease Inhbitors
SE0402790D0 (sv) HCV Protease Inhbitors
SE0402562D0 (sv) HCV Protease Inhbitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties